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a b s t r a c t
INTRODUCTION: Lynch syndrome and Crohn’s disease are two entirely separate conditions but each have
major gastrointestinal characteristics and carry a substantial increase in the risk of intestinal malignancy.
Their co-existence in the patient who is the subject of this report dictated the need for an individualised
treatment plan to deal with both conditions adequately.
PRESENTATION OF CASE:We report a case of a 51 year old female with a past medical history that includes
Lynch syndrome and small bowel Crohn’s disease. Over a period of ﬁfteen months, she developed three
separate primary metachronous tumors in her endometrium, colon and duodenum.
DISCUSSION: A patient with a combination of Lynch syndrome and ileal Crohn’s disease presents sig-
niﬁcant therapeutic implications that are not usually present when these conditions are treated in
isolation.
CONCLUSION: The surgical treatment of patients with Lynch syndrome requires a sound knowledge of
the possible neoplastic conditions that can arise in the syndrome. Early detection is paramount, either by
implementation of evidence based surveillance programs or at least by a heightened clinical awareness
of the features of this disease. Ideally this will result in both reduced surgical morbidity and improved
oncologic outcome. Furthermore, the medical treatment of Crohn’s disease in a patient with tumors
arising from Lynch syndrome must be undertaken with at least a consideration of the possibility that the
use of immunosuppressive medication might increase the risk of cancer recurrence.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Lynch syndrome, described as a family cancer syndrome by
Henry Lynch in 1966, is an autosomal dominant genetic disorder
that carries a high risk for the development of colon cancer and
several other types of cancer including endometrial, ovarian and
small bowel cancer [1]. The syndrome arises from a mutation in
the genes (MSH2, MLH1, MSH6 or PMS2) responsible for the repair
of DNA mismatch errors that arise during DNA replication [2].
Lynch later named the syndromehereditarynonpolyposis colon
cancer (HNPCC). However, as other cancers were later seen to be
part of the syndrome, the term Lynch syndrome has been restored
to avoid the misleading use of HNPCC, which refers only to colorec-
tal cancer [3].
Cancers of the stomach, small bowel, endometrium, ovaries
and urothelium have all been found in Lynch syndrome. However,
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the commonest malignancy is colon cancer with a lifetime risk of
greater than 50% for its development and accounting for more than
2% of all newly diagnosed colorectal cancers [4–6].
Crohn’s disease is an inﬂammatory disease of unknown aeti-
ology, primarily affecting the gastrointestinal tract. Presenting
symptoms include abdominal pain, diarrhoea, bowel obstruc-
tion and intra-abdominal sepsis [7]. Complications can include
intestinal perforation, intra-abdominal abscess, internal ﬁstulas,
strictures and complex perianal disease. Crohn’s disease also car-
ries an increased risk of small bowel and colorectal cancer, and
its incidence and prevalence are rising [7,8]. Medical management
includes the use of immunomodulators and corticosteroids, which
cancause immunosuppression [7]. Surgical intervention is required
for patients with failed medical therapy or surgical complications.
There is no known association between Crohn’s disease and
Lynch syndrome. The occurrence of the two conditions creates
unique challenges as treatment options for one disease might
impact on the management of the other. These challenges are dis-
cussed in the reported case below.
http://dx.doi.org/10.1016/j.ijscr.2015.03.034
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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2. Presentation of case
A 51 year old female with a 24 year history of Crohn’s dis-
ease involving the terminal ileum presented with postmenopausal
bleeding. She also had a family history of Lynch syndrome and
previous genetic testing had conﬁrmed that she carried an MLH1
mutation. A hysteroscopy conﬁrmed the presence of endometrial
cancer. She underwent a laparoscopic assisted hysterectomy, bilat-
eral salpingo-oophorectomy and pelvic lymph node dissection.
Histopathology revealed a grade one endometrial cancer. Immuno-
histochemistry conﬁrmed a loss of staining for MLH1. She made an
uneventful postoperative recovery.
Three months after hysterectomy she was referred by her
general practitioner for a colorectal surgery opinion regarding
worsening symptoms of Crohn’s disease and known Lynch syn-
drome. A colonoscopy was performed and revealed an ulcerated
lesion in the caecum. Biopsies demonstrated inﬂammatory tis-
suewith associatedmoderate dysplasia. Colonoscopy also revealed
multiple pseudopolyps at the rectosigmoid junction alongwith fea-
tures of a sigmoid ﬁstula. A CT scan demonstrated a mass involving
thickened ileal loops and sigmoid colon representing an ileosig-
moid ﬁstula. A serum carcinoembryonic antigen (CEA) level was
elevated at 52.6g/L (normal level <5g/L).
Despite the negative biopsy, clinical suspicion of a carcinoma
remained high. Given the combination of Crohn’s disease with a
likely carcinoma of the caecum related to the Lynch syndrome,
surgical management required careful consideration.
For patients with Lynch syndrome and colon cancer, a total
colectomy and ileorectal anastomosis is usually recommended,
because of the high risk of metachronous colon tumors and a rel-
atively low risk of rectal tumors [9–11]. However total colectomy
has an adverse impact on bowel function, which would likely be
substantially worse in this patient given the need for a signiﬁcant
ileal resection, required for her Crohn’s disease.
Under these circumstances, the surgery recommended was a
right hemicolectomy with associated terminal ileal resection along
with resection of the sigmoid colon due to the presence of the
ileosigmoid ﬁstula. This would deal with the two separate condi-
tions of likely caecal cancer and ileal Crohn’s disease. Although the
ﬁstula to the sigmoid colon might have been managed by simple
closure, resection was recommended to prevent tumor “seeding”
along the ﬁstula track.
Surgery proceeded as described and the postoperative recov-
ery was uneventful. Histopathology demonstrated a moderately
differentiated adenocarcinoma of the caecum with no lymphovas-
cular involvement and no metastases in regional lymph nodes.
Crohn’s disease was conﬁrmed in the ileum and sigmoid colon,
and resection margins for both cancer and Crohn’s disease were
negative. Immunohistochemistry revealed a loss of staining of the
MLH1 protein as expected. Given the absence of unfavourable his-
tologic features and the known better prognosis for patients with
colon cancer in Lynch syndrome, adjuvant chemotherapy was not
recommended [12].
Given the circumstances, regular follow up was undertaken.
Nine months following the bowel resections, the patient was well
and without signs of metastases but was found to have iron deﬁ-
ciency anemia with a hemoglobin of 106g/L. Iron studies recorded
a serum iron of 5mol/L and ferritin of 8ng/ml. A gastroscopy and
colonoscopy were performed. Colonoscopy demonstrated a nor-
mal colorectal remnant but gastroscopy revealed a 2.0×1.5 cm ﬂat
lesion with central ulceration in the third part of the duodenum.
Biopsies revealed a poorly differentiated adenocarcinoma. Capsule
endoscopy of the small bowel conﬁrmed the duodenal lesion and
excluded other lesions in the small bowel.
Duodenal resection was undertaken and again the patient made
an uneventful recovery. Histologic examination of this third tumor
indicated this was a new primary tumor conﬁned to the duodenal
wall.
After a further twelve months of follow up, the patient remains
well with no evidence of new primary tumors or of metastatic dis-
ease. In the absence of any recurrence of her Crohn’s disease, no
medical treatment for Crohn’s disease has been instituted.
3. Discussion
This case is noteworthy because of the presentation of three
metachronous tumors in the context of Lynch syndrome combined
with ileal Crohn’s disease and an ileosigmoid ﬁstula. This combi-
nation of diseases had signiﬁcant therapeutic implications that are
not usually relevant when the conditions are treated in isolation.
In a patient with Lynch syndrome, the risk of a second colon
tumor after treatment for a primary colon tumor by segmental
colectomy is 16% after ten years [13]. Not surprisingly, many of
the guidelines published on the management of Lynch syndrome
recommend that a total colectomy should be considered, particu-
larly for younger patients with Lynch syndrome presenting with
colon cancer [14].
However, the surgical management for Crohn’s disease in this
patient required an ileal resection, the extent of which would be
dictated by the amount of ileum involved.
To treat both conditions in the sameway aswhen they appear in
isolation would combine a possibly extensive ileal resection with
a total colectomy that would very likely result in extremely poor
bowel function. In view of that, an alternative surgical approach
was considered and it was determined after discussion with the
patient, that total colectomy should be avoided and an ileal resec-
tion with a right hemicolectomy along with a segmental sigmoid
colon resection be performed in an effort to preserve a signiﬁcant
colonic remnant and thereby reduce the impact of surgeryonbowel
function and quality of life. Furthermore, as at least 30% of patients
who have had one resection for Crohn’s disease will require a fur-
ther resection within ﬁve years, this added another reason to avoid
total colectomy [15].
As the surgery undertaken in this case has left the patient with a
substantial colonic remnant, regular colonoscopic surveillance was
seen as particularly important.
There is debate about how frequently this surveillance should
be undertaken in Lynch syndrome, with recommendations gener-
ally being for a period of between one and three years [16]. The
AustralianNational Health andMedical Research Council (NHMRC)
guidelines recommend yearly colonoscopy and this is the program
thatwas suggested to our patient [17]. Givenher subsequent devel-
opment of duodenal cancer, there may also be a place for regular
gastroduodenoscopy and capsule endoscopy of the small bowel
although the evidence base for these recommendations is limited
[14,18].
Of further note in the management of this patient, it is recog-
nised that some immunosuppressive drugs used in the treatment
of Crohn’s disease are associated with an increased risk of certain
types of cancer, including skin cancers and lymphomas [19,20].
There is little evidence to suggest an increase in the incidence of
metastatic cancer of any nature in patients taking these medica-
tions, but the potential for these drugs to induce cancer should at
least be considered before they are prescribed for patients who
have suffered multiple episodes of other forms of malignancy.
4. Conclusion
This case highlights the necessity for an individualised
treatment plan in a patient who presented with two serious gas-
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trointestinal conditions associated with Lynch syndrome (caecal
cancer) and Crohn’s disease (a symptomatic ileo-sigmoid ﬁstula).
Of further note in this case is the presence of three separate pri-
mary cancers arising over a less than two year period in the context
of Lynch syndrome. Whilst clearly a possibility, this situation has
not previously been encountered by the senior author despite him
having treated a large number of patients with Lynch syndrome
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